Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial Meeting Abstract
| Authors: | Bedke, J.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C.; Gurney, H.; Kessler, E. R.; Retz, M.; George, S.; Escudier, B.; Zhang, J.; Simsek, B.; Scheffold, C.; Motzer, R. J.; Choueiri, T. K.; Apolo, A. B. |
| Abstract Title: | Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (Hybrid-Kongress) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 44 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Oct 01-04 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2021-09-01 |
| Start Page: | 24 |
| End Page: | 25 |
| Language: | English |
| ACCESSION: | WOS:000760622600046 |
| PROVIDER: | wos |
| DOI: | 10.1159/000518417 |
| Notes: | Meeting Abstract: V189 -- Meeting was also presented virtually -- "Joint Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology (Hybrid Congress)" -- Source: Wos |
